The potential of sodium glucose cotransporter 2 (SGLT2) inhibitors to reduce cardiovascular risk in patients with type 2 diabetes (T2DM)

被引：48
作者：
Basile, Jan N. [1 ]
机构：
[1] Med Univ S Carolina, Seinsheimer Cardiovasc Hlth Program, Charleston, SC 29425 USA
来源：
JOURNAL OF DIABETES AND ITS COMPLICATIONS | 2013年 / 27卷 / 03期
关键词：
INADEQUATE GLYCEMIC CONTROL; DOUBLE-BLIND; BODY-WEIGHT; ADD-ON; DAPAGLIFLOZIN; MELLITUS; CANAGLIFLOZIN; METFORMIN; INSULIN; HYPERGLYCEMIA;
D O I：
10.1016/j.jdiacomp.2012.12.004
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Type 2 diabetes mellitus (T2DM) significantly increases morbidity and mortality from cardiovascular disease (CVD). Treatments for patients with T2DM have the potential to reduce cardiovascular (CV) risk. This review focuses on the potential of a new class of antidiabetic agents, the sodium glucose cotransporter 2 (SGLT2) inhibitors, to reduce CV rsk in patients with T2DM through reductions in hyperglycemia, blood pressure (BP), and body weight. The results of clinical trials of SGLT2 inhibitors are summarized and discussed. (C) 2013 Elsevier Inc. All rights reserved.
引用
收藏
页码：280 / 286
页数：7
相关论文
共 72 条
  • [11] Fate of the beta-cell in the pathophysiology of type 2 diabetes
    Campbell, R. Keith
    [J]. JOURNAL OF THE AMERICAN PHARMACISTS ASSOCIATION, 2009, 49 : S10 - S15
  • [12] Cefalu W. T., 2012, DIABETES S1A, V61, P10
  • [13] American Diabetes Association-European Association for the Study of Diabetes Position Statement: Due Diligence Was Conducted
    Cefalu, William T.
    [J]. DIABETES CARE, 2012, 35 (06) : 1201 - 1203
  • [14] Evolving Treatment Strategies for the Management of Type 2 Diabetes
    Cefalu, William T.
    [J]. AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 2012, 343 (01) : 21 - 26
  • [15] Cefalu William T, 2009, Cleve Clin J Med, V76 Suppl 5, pS39, DOI 10.3949/ccjm.76.s5.06
  • [16] Solute carrier family 2, member 9 and uric acid homeostasis
    Cheeseman, Chris
    [J]. CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 2009, 18 (05) : 428 - 432
  • [17] Key considerations in pharmacotherapy for type 2 diabetes mellitus: a multiple target organ approach
    Cornell, S.
    [J]. JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2012, 37 (03) : 254 - 259
  • [18] National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants
    Danaei, Goodarz
    Finucane, Mariel M.
    Lu, Yuan
    Singh, Gitanjali M.
    Cowan, Melanie J.
    Paciorek, Christopher J.
    Lin, John K.
    Farzadfar, Farshad
    Khang, Young-Ho
    Stevens, Gretchen A.
    Rao, Mayuree
    Ali, Mohammed K.
    Riley, Leanne M.
    Robinson, Carolyn A.
    Ezzati, Majid
    [J]. LANCET, 2011, 378 (9785) : 31 - 40
  • [19] The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia
    DeFronzo, R. A.
    Davidson, J. A.
    Del Prato, S.
    [J]. DIABETES OBESITY & METABOLISM, 2012, 14 (01) : 5 - 14
  • [20] Overview of Newer Agents: Where Treatment Is Going
    DeFronzo, Ralph A.
    [J]. AMERICAN JOURNAL OF MEDICINE, 2010, 123 : S38 - S48
12345678